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Pancreatic cancerBackground: Patients with pancreatic carcinoma have a grim prognosis. Here, we examine the induction
of an in vitro antibody response of human B cells to pancreatic carcinoma antigens.
Material and methods: Cells of five cultured pancreatic ductal adenocarcinoma lines were lysed and their
plasma membrane fragments isolated in an aqueous two-phase-system. The plasma membrane frag-
ments were then added to cultures of isolated peripheral blood mononuclear cells from healthy volun-
teers for 14 days to act as a tumor antigen. Also, we added combinations of IL-2, IL-4, IL-21, anti-CD40
mAb and varying protein concentrations of the plasma membrane fragments to these cultures. We then
tested characteristics and binding of resulting IgG and IgM against aforementioned tumor plasma mem-
brane fragments and their respective cells using ELISAs.
Results: The combination of IL-2, IL-4 and anti-CD40 mAb elicited IgM production showing significant
binding (p < 0.05) to plasma membrane fragments. PANC-1 antigen and the combination of IL-4, IL-21
and anti-CD40 mAb was able to produce a significant and specific IgG formation against PANC-1 plasma
membrane fragments (p < 0.05). Tumor antigen, interleukins and anti-CD40 mAb had a significant impact
on the binding capacity of these antibodies (p < 0.05). IgG binding pancreatic carcinoma cells was
observed when the tumor antigen concentration was increased during stimulation (p < 0.05). BxPC3
plasma membrane fragments showed inhibitory effects on IgG binding BxPC3 antigens (p < 0.05).
Conclusions: A human anti-tumor antibody formation can be induced in vitro using PANC-1 antigens and
B cell stimulating agents. This response has the potential to generate antibodies specific to PANC-1
antigens.
Précis: The concept presented is novel and a promising approach to eliciting a specific B cell response to
tumor antigen. The method may prove useful in understanding and developing anti-tumor immunity.
 2016 The Authors. Published by Elsevier Inc. This is anopenaccess article under theCCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction Therapy of solid tumors with monoclonal antibodies has gainedThe prognosis of patients with pancreatic carcinomas remains
extremely poor. Even complete tumor resection has a limited
impact on the course of disease due to frequent and early cancer
recurrence [1]. Especially in the cases of successful surgical resec-
tion, effective therapeutics to treat residual tumor cells are needed.significance in the past years and improved cancer survival rates
for several tumor entities. Patients with colorectal cancer, for
example, have benefited from these advances. In clinical trials,
bevacizumab, an antibody inhibiting angioneogenesis, has been
shown to improve survival rates in combination with established
chemotherapeutic agents [2]. In a series of approvals from the
FDA (2004, 2013), bevacizumab has become a standard agent in
the treatment of metastasized colorectal cancer. Also, anti-EGFR-
mAbs such as cetuximab and panitumumab have been shown to
better the outcome in the cases of KRAS wild type tumors [3].
However, patients with pancreatic carcinoma have not benefited
from these developments. Neither trials using a combination of
gemcitabine and bevacizumab nor trials using the combination
of gemcitabine with cetuximab were superior to gemcitabine
alone [4,5].
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response from human lymphocytes to human pancreatic tumor
cells without prior definition of target antigens. We used cell mem-
brane preparations from pancreatic tumor cells as antigens in com-
bination with other immunostimulant agents. The goal was to
create an in vitro model to generate antibodies against pancreatic
cancer antigen.
2. Materials and methods
This study and all experiments conducted were approved by the
local ethics committee of the university clinic Freiburg.
2.1. Isolation of lymphocytes
Lymphocytes from healthy volunteers were isolated from 48 ml
of EDTA blood (n = 9). Cell separation was achieved by Ficoll den-
sity gradient centrifugation, and cells were washed twice in RPMI
1640 and fetal calf serum. Cell viability was determined by trypan
blue staining. Only preparations with more than 95% viable cells
were used for further experiments.
2.2. Cell lines
Pancreatic ductal adenocarcinoma (PDAC) cell lines (PANC-1,
BxPC3, MIA-PACA2, CAPAN-2, HPAF) and the human embryonic
kidney cell line HEK-293 were maintained in Dulbecco’s modified
Eagle medium containing 10% FCS up to densities of 90% before
being split 1:5. Cells were grown at 37 C in a humidified environ-
ment at 5% CO2.
2.3. Isolation of plasma membrane fragments (PMFs)
Enrichment of cell membrane fragments was performed by sub-
cellular fractioning. The PDAC cells were lysed by two cycles of
freezing and thawing. Further breakdown of the cells was achieved
by sonicating the cell lysates for 2 h at 4 C. Lysates were then sep-
arated in a two-phase aqueous system consisting of PEG-3350 and
dextran T 500. The PEG phase was then subjected to ultracentrifu-
gation at 100,000g for 80 min at 4 C. The precipitate was sus-
pended in PBS, and the protein concentration of that suspension
was determined by a BCA assay according to the manufacturer’s
instructions (Pierce, Rockford, USA). Enrichment of plasma mem-
branes was confirmed by determining the 50nucleotidase activity
with a malachite green phosphate assay kit (Cayman Chemical
Company, Ann Arbor, USA) according to the supplier’s instructions.
Integrity of the proteins after enriching for cell membrane proteins
was confirmed by SDS-PAGE on a 10% gel and Coomassie staining.
2.4. In vitro stimulation of lymphocytes
PBMCs were kept in 12-well plates at a concentration of
3  106 cells/well. 2–3 ml of RPMI 1640 medium/well (Invitrogen,
Paisley, UK) supplemented with 10% fetal calf serum (PAA, Pasch-
ing, Austria) were added to each well. PMFs of the cancer cell lines
served as tumor antigen in various concentrations. IL4, IL2, IL21
and anti-CD40 mAb concentrations were varied in several experi-
ments. We used PBMCs not presented with tumor antigen as a con-
trol. In all experiments, the supernatant medium was extracted
after 14 days of lymphocyte stimulation and used for further
examination. The concentration of ingredients per ml used for
the stimulations were 5 lg/ml of anti-human-CD40 mAb (R&D
Systems, Wiesbaden, Germany), 10 ng/ml of IL-2 (R&D Systems,
Wiesbaden, Germany), 100 ng/ml of IL-4 (R&D Systems, Wiesbaden
Germany), 100 ng/ml of IL-21 (R&D Systems, Wiesbaden Germany)and 10 lg of antigen protein/ml (enriched PDAC plasmamembrane
proteins), unless mentioned otherwise.
2.5. ELISA
Determining the antibody concentration of the supernatants
was performed by coating multiwell plates with goat anti human
IgG (Jackson Immuno Research, West Grove, PA, USA) in concentra-
tions ranging between 80 and 2560 ng/ml (standard curve). Ran-
dom binding sites were blocked with 10% normal goat serum,
after which 100 ll/well of supernatant was added. Finally, a horse
radish peroxidase coupled anti human IgG antibody (Pierce, Rock-
fort, IL, USA) was added and the reaction was stopped after one
hour using Tetramethylbenzidine. Absorbance was measured at
k = 405 nm.
For assaying antibodies binding PDAC antigens, wells were
coated with 10 lg of PMF protein/ml per PDAC cell line in carbon-
ate buffer at 4 C overnight. Unspecific binding sites were blocked
with 10% normal goat serum. Supernatants were incubated at 4 C
overnight before antibody binding was detected by 2 ng/ml alka-
line phosphatase conjugated goat anti human IgG Fcc (Jackson
Immuno Research, West Grove, PA, USA) or 2 ng/ml AP conjugated
goat anti human IgM Fc5l (Jackson Immuno Research, West Grove,
PA, USA). After final washing, binding of secondary antibody was
detected by para-Nitrophenylphosphate (pNPP) substrate (KPL,
Gaithersburg, MD, USA). Absorbance was measured at 405 nm
after stopping the color reaction with 5% EDTA solution.
To detect antibodies capable of binding intact PDAC cells, estab-
lished pancreatic tumor cell lines were grown in 96 well plates up
to a density of 75%. Cells were fixed with methanol at 20 C and
unspecific binding sites were blocked with 10% normal goat serum.
The samples were stored at 4 C overnight and after washing, sec-
ondary horseradish peroxide conjugated goat anti human IgG Fcc
or horseradish peroxide conjugated goat anti human IgM Fc5l
was applied for 2 h at room temperature. Binding of secondary
antibodies was detected by addition of pNPP substrate and extinc-
tion was determined at 405 nm after stopping the color reaction
with 5% EDTA solution.
2.6. Statistics
Statistics were calculated with Microsoft Excel (Microsoft,
Redmond, Washington) and SPSS software (IBM, Armonk, New York).
Data were checked for normal distribution with the Shapiro-Wilk
test. Kruskal-Wallis and Mann-Whitney-U tests were used to com-
pare groups. P-values <0.05 were considered statistically
significant.3. Results
3.1. PANC-1 antigen is necessary for IgM reactivity – IL-2 and IL-4
increased antibody binding to tumor cells
We tested the necessity of tumor antigen and a selection of sup-
posed B cell stimulating agents for antibody reactivity to tumor
antigen (PMF). We selectively stimulated PBMCs with anti-CD40
mAb, IL-2, IL-4 and PANC-1 PMFs, the tumor antigen. We measured
IgM reactivity to PANC-1 PMFs and cells with ELISAs.
Tumor antigen (PMF) was necessary for IgM reactivity
towards the PANC-1 PMFs. Together with anti-CD40, it elicited
more IgG binding the antigen (p > 0.05). Further addition of IL-
2 alone, as well as IL-2 and IL-4, also increased IgM binding
tumor antigen (p > 0.05). Interestingly, solely adding IL-4 to
anti-CD40 mAb inhibited IgM reactivity towards tumor antigen
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an-CD40 mAb + + + + + 
IL-4     + +  + 
IL-21      + + + 
Fig. 2. In vitro stimulation of peripheral blood mononuclear cell (PBCMs) with
PANC-1 antigen, anti-CD40 mAb, IL-21 and IL-4 significantly increase IgG binding to
PANC-1. Human PBMCs were incubated with PANC-1 plasma membrane fragments
(PMFs) in the presence of anti-CD40 antibody, IL-21, and IL-4. After 14 days, IgG
binding to PANC-1 PMFs was examined. PBMCs stimulated with all of these
compounds and tumor antigen PANC-1 produced the most reactive IgG antibodies
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Fig. 1. IgM binding to PANC-1 plasma membrane fragments (PMFs) is dependent
on previous lymphocyte stimulation. Human peripheral blood mononuclear cell
were incubated with PANC-1 PMFs in the presence of anti-CD40 antibody, IL-2, and
IL-4. After 14 days IgM in the supernatants was examined for binding to PANC-1
PMFs. IgM binding to PANC-1 PMFs was significantly decreased when lymphocytes
were not stimulated with tumor antigen or when only stimulated with tumor
antigen, anti-CD40 mAb, and IL-4 (n = 5 independent experiments, *p < 0.05).
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cell line HEK-293 was also examined. These antibodies bound
PANC-1, MIA PaCa-2 as well as the control HEK-293. Further-
more, stimulating PBMCs with IL-2, IL-4 and anti-CD40 mAb pro-
duced a similar IgG reaction.
3.2. PANC-1 antigen, anti-CD40 mAb, IL-21 and IL-4 stimulation
induces a specific and significant IgG response to PANC-1 antigen
We tested another stimulation protocol using IL-4, IL-21, anti-
CD40 mAb and PANC-1 PMFs [10 lg/ml] as tumor antigen. The
IgG enriched supernatants were tested for PANC-1 plasma mem-
brane binding. IL-21 increased IgG binding PANC-1 PMFs. In con-
trast, IL-4 alone did not increase binding. Also, IL-21, IL-4 and
anti-CD40 mAb did not show significantly increased IgG binding
of PANC-1 PMFs without tumor antigen. Together with PANC-1
antigen however, lastly mentioned combination produced a signif-
icantly increased reactive IgG toward PANC-1 PMFs (Fig. 2).
We continued to use IL-4, IL-21 and anti-CD40 mAb with vary-
ing antigens, the control consisting of omitting any antigen alto-
gether. We then tested the resulting IgG against PANC-1 PMF.
Importantly, only when using PANC-1 antigen during stimulation
were we able to see IgG reactivity toward PANC-1 antigen (Fig. 3a).
Furthermore, when testing IgG binding various antigens after
PANC-1 antigen stimulation, the resulting IgG showed significantly
higher affinity to PANC-1 PMFs than to negative control HEK-293
PMF. Interestingly, no statistically significant difference was
observed when testing the same IgG against various PDAC antigens
(MIA PaCa-2, BxPC3, CAPAN-2 and HPAF) for potential cross-
reactivity between PDAC lines (Fig. 3b).
However, while some of these IgG also showed reactivity
toward PANC-1 cells, they did not do so unanimously using this
stimulation protocol (p > 0.05). In individual cases, reactivity of
IgG toward both PANC-1 PMFs and cell surfaces was detected.
3.3. BxPC3 inhibits the formation of antibodies capable of binding
BxPC3 antigen
We went on testing other PDAC (BxPC3, MIA PaCa-2, CAPAN-2,
HPAF) and the HEK-293 cell lines with the same stimulationprotocol (n = 6 each). IL-4, IL-21, anti-CD40 mAb served as B cell
stimulating agents and plasma membrane preparations were
added to the stimulation medium as. PBMCs were cultured for
14 days. IgG in the supernatants were examined for their respec-
tive PMF and intact cell binding.
Unexpectedly, antibodies from B cells in contact with BxPC3
antigen during stimulation showed significantly decreased binding
to BxPC3 antigen itself (Fig. 4).
The cell lines MIA PaCa-2, CAPAN-2, HPAF and HEK-293 did not
produce significantly reactive or specific antibodies to their respec-
tive PMFs or cells. Also, the IgG from B cells stimulated with these
cell fragments showed no specificity or significant cross reactivity
between the different carcinoma cell lines.3.4. Most PDAC antigens decreased absolute IgG production
To further investigate the reduced binding behavior of IgG
depending on the PDAC antigen, we measured the IgG concentra-
tion of the supernatants after stimulation via ELISAs (n = 6).
Remarkably, PANC-1PMF was the only antigen not to significantly
reduce the absolute IgG production (Fig. 5).3.5. High PANC-1 antigen concentration induced more reactive IgG to
PANC-1 cells
We varied the protein concentration of two PMFs (PANC-1 and
BxPC3) added to PBMC cultures (5, 10 and 20 lg/ml) to test the
effect on IgG binding and potential toxicity. PBMCs were stimu-
lated with IL-4, IL-21 and anti-CD40 mAb (n = 2). The control con-
sisted in omitting the antigen. We tested the binding of the
resulting IgG in supernatants against their respective cells
(PANC-1 and BxPC3). IgG binding to PANC-1 cells increased with
rising PMF concentrations. 20 lg/ml significantly increased bind-
ing cells in comparison to the control (Fig. 6). Varying PMF concen-
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No smulants IL-4, IL-21, an-CD40 mAb 
Fig. 3. IgG production after PANC-1 antigen exposure is specific after peripheral blood mononuclear cell (PBMC) stimulation with IL-4, IL-21 and anti-CD40 Ab. Human
PBMCs were incubated with PANC-1 plasma membrane fragments (PMFs) in the presence of anti-CD40 antibody, IL-21, and IL-4 (‘‘stimulants”) for 14 days. The control
consisted of omitting tumor antigen during that time period. a: After stimulation with various PMFs, IgG from PBMCs were tested against PANC-1 PMFs. Only PANC-1 PMFs in
concert with IL-4, IL-21 and anti-CD40 Ab provoked a specific IgG response to PANC-1 PMFs (n = 8 independent experiments, *p > 0.05). b: After PANC-1 antigen and IL4, IL-21
and anti-CD40 Ab exposure, IgG from PBMCs (‘‘PANC-1 IgG”) were tested against various antigens to test for specificity. They showed significantly more binding to PANC-1

















Smulang angen (PMFs) 
Various IgG vs. BxPC3 PMFs 
No smulants IL-4, IL-21, an-CD40 mAb 
Fig. 4. BxPC3 inhibits the formation of antibodies reactive to BxPC3 antigen.
Human peripheral blood mononuclear cells (PBMCs) were incubated with BxPC3
plasma membrane fragments (PMFs) in the presence of anti-CD40 antibody, IL-21,
and IL-4 (‘‘stimulants”) for 14 days. The control consisted of omitting tumor antigen
and testing the antibodies against BxPC3 PMFs. BxPC3 PMFs reduced IgG reactivity
from PBMCs stimulated with IL-4, IL-21 and anti-CD40 mAb towards BxPC3 antigen






















Fig. 5. IgG concentration in supernatants from peripheral blood mononuclear cell PBM
Human PBMCs were incubated with various PDAC and HEK293 plasma membrane fragm
14 days. The control consisted of omitting tumor antigen. The concentration of IgG was
HEK-293 lead to significantly lower concentrations of IgG than the control. There was no
*p < 0.05).
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The role of B cells and the humoral immune system in anti-
tumor immunity is understood only rudimentarily [6]. There are
numerous studies that suggest that B cells inhibit effective anti-
tumor immunity [7,8], some showing tumor specific antibodies
to be associated with a detrimental prognosis [9]. On the other
hand, multiple studies have shown that antibodies and B cells inhi-
bit tumor growth and progression [10–12]. In an important effort
to find antibodies against pancreatic cancer lesions, Gold et al.
vaccinated mice with mucin purified from human pancreatic can-
cer cells [13]. The resulting IgG1 antibody PAM4 has since
been applied in diagnosis and radioimmunotherapy in various tri-
als [14].
In this study, we have established an in vitro method to elicit
production of antibodies binding to PDAC antigen. We demon-
strate that PANC-1 antigen can trigger an antibody response and
is necessary for specific and significant antibody production
(Figs. 1–3). We attempted to modulate this antibody response
using various B cell stimulating cytokines: IL-4 has been shown
to increase B cell longevity and induce a class switch from IgM to
IgG [15,16]; IL-2 has been associated with B cell growth, differen-
tiation and induction of IgM secretion [17]. IL-2 or IL-2 and IL-4 did* 




IA PaCa-2 Capan HPAF HEK-293 
g Angen (PMFs) 
IL-4, IL-21, an-CD40 mAb 
Cs stimulated with IL-4, IL-21, anti CD40 antibodies and various tumor antigens.
ents (PMFs) in the presence of anti-CD40 antibody, IL-21, and IL-4 (‘‘stimulants”) for
then measured via ELISA. Fragments from BxPC3, MIA PaCa-2, CAPAN-2, HPAF and
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Fig. 6. Effect of varying PMF protein concentration on IgG binding PANC-1 PMFs and intact cells. Human peripheral blood mononuclear cells (PBMCs) were incubated with
PANC-1 plasma membrane fragments (PMFs) in the presence of anti-CD40 antibody, IL-21, and IL-4 for 14 days. PMF protein concentration was varied (5, 10 and 20 lg/ml).
IgG binding PANC-1 cells increased with rising PANC-1 concentrations during stimulation. (n = 2 independent experiments, ⁄p < 0.05).
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are antibodies of low specificity [18]. But also IgG produced during
stimulation with IL-2, IL-4 and anti-CD40 mAb were neither reac-
tive nor specific to PANC-1.
We then tried using IL-21, which stimulates B cells to secrete
reactive antibodies and contributes to B cells’ survival when they
are co-stimulated by antigens and T cell signaling [19]. Further-
more, IL-21 can induce a class switch from IgM to IgG1 and IgG3
when accompanied by CD40 stimulation [20]. In one study, IL-21
only increased B cell proliferation together with IL-4, anti-IgM
and CD40 stimulation [21]. Our in vitro model also exposes the dif-
ferential regulation of IL-21, as it was the combination of IL-21, IL-
4 and anti-CD40 mAb that led to strong IgG binding capacity of the
PANC-1 cell membrane preparations used for stimulating the lym-
phocytes (Fig. 2). This corroborates the notion of differential regu-
lation of B cells by interleukins.
Using the same stimulation protocol, we show that IgG pro-
duced after exposure to PANC-1 antigen were PANC-1 PMF specific
(Figs. 2 and 3). There was no statistical difference between PANC-1
binding and binding of various other PDAC PMFs (MIA PaCa-2,
BxPC3, CAPAN-2, HPAF) (Fig. 3b). This raises the question of
whether IgG binding PANC-1 antigen cross-react to the same or a
similar antigen from other PDAC cell lines.
These IgG also showed binding to PANC-1 cells in half the cases.
These results did not reach statistical significance, though. When
we tested higher concentrations of PANC-1 PMF, we detected
increasing IgG binding to PANC-1 cells with rising concentration
(5–20 lg/ml) (Fig. 6).
In the case of PANC-1, we triggered a humoral response against
pancreatic tumor cell surfaces without a priori knowledge of which
antigen would be bound. This approach is feasible. Such an
exploratory immune-mediated scanning technique for eligible
therapeutic candidates may be applicable not only in pancreatic
carcinoma research, but in the case of other tumor entities as well.
Using the same stimulation protocol, the BxPC3 cell line yielded
contrasting results to PANC-1. In this case, IgG reactivity to BcxPC3
PMFs was significantly reduced, regardless of usage of IL-4, IL-21
and anti-CD40 mAb (Fig. 4). We assume that this inhibition of B
cell function is due to some feature of the BxPC3 cell or PMF.
Tumors are believed to inhibit the immune system to evade elim-
ination [22], some by emitting chemokines such as TGF-b or other
immunosuppressive cytokines [23,24]. Whether tumors inhibit B
cell action remains unclear. We suppose that BxPC3 had an inhibi-
tory effect on the PBMCs, accounting for the significantly decreased
reactivity towards BxPC3 antigens.
We further used PDAC cell lines MIA PaCa-2, CAPAN-2, HPAF
as well as HEK-293 applying the same protocol of IL-4, IL-21 andanti-CD40 mAb. They neither stimulated an antibody response like
PANC-1, nor did they inhibit one like BxPC3. These differing results
may be due to cell line specific surface antigens, i.e. PMF, profiles.
These findings underline the need for tumor individual approaches.
To further examine the differing results, we measured the IgG
concentration of supernatants after stimulating with IL-4, IL-21,
anti-CD40 mAb and tumor antigen. The concentration of MIA
PaCa-2, CAPAN-2, HPAF, HEK-293 and BxPC3 were significantly
lower than the control. PANC-1 was the only cell line not to show
a suppressed antibody concentration (Fig. 5). It may be that the
higher concentration of IgG after PANC-1 stimulation was impor-
tant to our PANC-1 findings.
We have developed an in vitro model to trigger a human anti-
tumor antibody response using tumor membrane fragments. The
fact that PANC-1 PMFs elicited a specific IgG response and BxPC3
PMFs suppressed lymphocyte function is particularly intriguing.
Both PMFs appear to trigger diametrically opposed mechanisms
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